Now I have all the information I need. Let me write the consolidated review.

## Summary

This paper proposes the Constraint Transformer (CT), an offline inverse constrained RL framework for safe decision-making in healthcare. CT addresses two key limitations of prior ICRL methods in medical settings: (1) it uses a causal attention mechanism with a Non-Markovian layer to incorporate patient history into constraint modeling, overcoming the Markov assumption; and (2) it introduces a model-based offline RL approach to generate "violating" (unsafe) trajectories from expert-only data, enabling constraint inference without an interactive environment. Experiments on sepsis and mechanical ventilation tasks using the MIMIC-III dataset show that CT reduces clinically unsafe behaviors (excessive doses, abrupt changes) to zero and improves the safety alignment of several CRL algorithms.

## Strengths

1. **Non-Markovian constraint modeling captures meaningful temporal dependencies.** The causal attention mechanism with the Non-Markovian weighted-cost layer demonstrably matters: Figure 3 shows that removing the attention layer causes cost values to lose their correlation with mortality rates, whereas the full CT produces costs that increase monotonically with mortality. The cost function also distinguishes between safe and unsafe physiological ranges (Figure 4), supporting interpretability.

2. **CT empirically eliminates clinically defined unsafe behaviors.** In the sepsis vasopressor task, CDT+CT reduces both "too high" vaso (>0.75 μg/(kg·min)) and "sudden change" (Δ>0.75) events to 0% — from 7.44% and 21.00% under DDPG, respectively (Table 3). This directly addresses the safety concerns that motivate the paper, and CT does so while administering some medication (max=0.11), unlike the zero-max (max=0.00) custom-cost baseline.

3. **CT improves multiple offline CRL algorithms and generalizes across methods.** When combined with VOCE, CopiDICE, BCQ-Lag, and CDT, CT improves ω over the corresponding no-cost and custom-cost baselines in nearly all cases (Table 2). The CDT+CT combination achieves the highest ω across all three DIFF metrics (IV: 57.15%, VASO: 65.20%, ACTION: 60.00%).

4. **Strong off-policy evaluation results on most metrics.** CDT+CT achieves the best results on 5 of 6 WIS-based OPE metrics and RMSE_IV (433.55 vs. 541.67 for the next best, CQL), as shown in Table 4. This provides evidence that the safe policies maintain reasonable quality according to multiple statistical estimators.

5. **The ω metric and DIFF-vs-mortality analysis provide a practical offline evaluation framework.** The paper defines ω as the survival rate among patients whose treatment least differs from the learned policy, alongside the established DIFF-vs-mortality graphical analysis. These are sensible evaluation tools for a setting where online environment interaction is impossible.

## Weaknesses

### Fatal
None.

### Major

1. **The DR estimate for CDT+CT is substantially worse than all baselines, and the paper does not adequately explain this gap.** CDT+CT has a Doubly Robust estimate of −3.08, compared to −0.14 for DQN and even −1.55 for the zero-drug (min) policy. This means the estimated expected return under CT's policy is far lower than even administering no drugs at all. The paper explains only that CT's RMSE_VASO and F1 scores are worse due to "safe and conservative" policies, but this does not account for why the DR estimate — which estimates *reward* (not safety-matching) — is so much worse than every baseline. The paper offers no discussion of DR estimator variance, the reward function's correlation with clinical outcomes, or why a safe policy would yield a DR estimate this low. This gap undermines the claim that CT produces both safe *and effective* policies. Direct mortality-relevant OPE or a discussion of why DR is unreliable here is needed.

2. **The validity of generated violating trajectories is not established, and the method's reliance on them is central.** The model-based offline RL is trained exclusively on expert (survivor) data and generates violating trajectories by setting a high target return. Actions that deviate significantly from expert behavior may cause the world model to operate out-of-distribution, producing unrealistic state transitions. The paper does not analyze whether generated trajectories are physiologically plausible (e.g., via comparison to real unsafe trajectories, manual inspection, or physiological plausibility checks). Without this, CT may learn to discriminate based on artifacts. The ablation results (Table 2, bottom) show the generative model outperforms DDPG, which provides some indirect validation, but this does not substitute for direct quality analysis of the violating trajectories.

3. **The gradient update (Equation 9) is a heuristic modification of the ICRL objective without principled justification.** Standard ICRL (Equation 4) compares expert trajectories to trajectories from a policy conditioned on the *current* constraint estimate. CT replaces the second term with static, pre-generated violating trajectories from a fixed model. The paper does not derive why this substitution is valid — e.g., whether the generator's distribution corresponds to any "violating" distribution that maximizes Equation 9, or whether there are convergence guarantees. The paper acknowledges this indirectly in the limitations ("Lack of rigorous theoretical analysis") but does not clarify the status of the method as a heuristic versus a principled objective. The empirical results are promising, but the theoretical gap is significant.

4. **Missing key details about baselines.** The "custom cost" and "LLMs cost" baselines are never adequately described. For LLMs cost: which LLM, what prompt, what constraints were produced? For custom cost: what was the cost function? Without this information, the reader cannot assess whether these are reasonable baselines or straw men. The paper also does not compare against any adapted ICRL method (online ICRL adapted to offline by replacing the inner-loop RL with offline CRL), which would be a natural and informative baseline.

### Minor

5. **The cost threshold κ is defined in the problem formulation but never reported or analyzed.** CRL's safety-efficacy tradeoff depends critically on κ (Equation 1). The paper never states what κ value was used in experiments or how results vary with it. This makes it harder to interpret the safety guarantees and reproduce the results.

6. **The ω metric has confounding issues that are not fully discussed.** ω measures survival among patients whose treatments are closest to the learned policy — essentially asking "does the policy agree with clinicians on patients who survived?" This conflates policy-clinician agreement with optimality. Patients who differ from clinicians may have different mortality for reasons unrelated to policy quality (e.g., unobserved severity). The paper acknowledges evaluation difficulties broadly but does not discuss this specific confound or its implications for interpreting the ω results.

### Trivial

7. **The scalar cost C(τ) and its relation to the binary constraint indicator.** The paper defines C(τ) as a weighted sum of per-timestep costs, but the original ICRL likelihood (Equation 2) uses an indicator 𝕀(τ) ∈ {0,1}. The paper should clarify how the scalar score maps to this indicator, especially since log(C) is used in the gradient.

## Nice-to-Haves

- **Direct analysis of generated violating trajectories**: A few manually inspected examples showing that generated "unsafe" trajectories correspond to physiologically meaningful unsafe behaviors (e.g., excessive doses leading to unrealistic vital signs vs. realistic dangerous trajectories) would substantially strengthen the paper's central claim.
- **Sensitivity analysis on κ**: Reporting results for a range of κ values would illuminate the safety-efficacy tradeoff.
- **DR decomposition**: Explaining why DR is so much worse for CT — e.g., reporting variance, or showing that the reward function penalizes deviations from clinician behavior and thus penalizes safety-focused policies — would address the most concerning gap in the evaluation.

## Removed Points

- **"Max dosage 0.11 is well below the typical therapeutic range (0.1–0.2)"**: Factually incorrect. 0.11 is within [0.1, 0.2] (at the low end but within range). The paper's own table caption states the range is 0.1–0.2. Removed as factually wrong.
- **Mechanical ventilation results mentioned but not shown**: The paper states these experiments exist; their absence from the main text is due to appendix stripping by the parser, not an author omission. Removed as a parser artifact.
- **"No empirical evidence" about the generative model**: The ablation (Table 2 bottom) shows the generative model outperforms DDPG (55.49% vs. 50.95% on IV DIFF), which is empirical evidence that the generation process has utility. Removed the absolute version of this claim; the remaining point about *physiological plausibility* validation is retained in Major #2.
- **Weakness about the LLMs cost baseline being "poorly described"**: Retained in Major #4 because the critic is right — the paper gives no details. But the claim that "these weak baselines inflate the apparent advantage" is too strong; the baselines are weak in the sense of being poorly described, not in the sense of being easy to beat. Removed the inflation claim, kept the under-description point.

## Novel Insights

The Strength Finder's observation that the attention layer ablation causes cost values to lose correlation with mortality (Figure 3) is genuinely informative: it shows that the non-Markovian weighting is not just a modeling nicety but is structurally necessary for the constraint to reflect clinical outcomes. The diagonal comparison across Table 2 — where CT improves ω for most CRL methods but the improvement magnitude varies substantially (e.g., VOCE gains ~12 points on VASO DIFF while BCQ-Lag essentially does not improve) — suggests that CT's benefit is method-dependent, which is an interesting pattern the paper does not explore. The contrast between CT's dominance on WIS-based metrics and its collapse on DR is also striking and deserves direct investigation rather than the brief hand-waving about conservatism.

## Suggestions

1. **Provide a head-to-head comparison against an adapted online ICRL method** (e.g., Malik et al. 2021 or Gaurav et al. 2022 with the inner-loop RL replaced by offline CRL). This is the most informative missing baseline.
2. **Show the physiological plausibility of generated violating trajectories** using metrics like physiological plausibility scores, comparison to real unsafe patient trajectories, or at least manual inspection examples.
3. **Address the DR gap directly**: either explain why DR is unreliable for CT (e.g., high variance due to the policy being far from the behavior policy), or provide a mortality-focused OPE analysis (e.g., WIS with mortality as reward).
4. **Report the value of κ used and show sensitivity analysis** over a range of κ values.
5. **Clarify the "custom cost" and "LLMs cost" baselines** with enough detail for replication.

## Score and Decision

The paper addresses an important real-world problem and introduces a creative combination of transformer-based constraint modeling with generative offline data augmentation for ICRL. The empirical results are promising in several respects (unsafe behavior elimination, improved ω, strong WIS-based OPE). However, the evaluation has significant gaps: the DR estimate suggests the learned policy may be severely suboptimal in terms of expected reward; the central mechanism of generating violating trajectories lacks validation of physiological plausibility; the gradient formulation is a heuristic without principled justification; and key experimental details (κ, baseline specifications) are missing. These are structural issues, not cosmetic ones, and they affect whether the paper's core claims are convincingly supported. A substantially strengthened version addressing these concerns would be a strong contribution.

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Reject</decision>